Literature DB >> 2356921

Development of vascular neoplasia in Castleman's disease. Report of seven cases.

W Gerald1, M Kostianovsky, J Rosai.   

Abstract

Seven cases of vascular neoplasia arising within lesions of hypervascular follicular hyperplasia (HFH) fulfilling the criteria of Castleman's disease are described. The patients did not have evidence of acquired immunodeficiency syndrome or other immunologic disorders. The masses were solitary and located in the retroperitoneum (five cases), mediastinum (one case), and axilla (one case). Grossly, they measured up to 20 cm and had a variegated appearance. In each case two morphologically distinct processes were present: a mesenchymal spindle-cell neoplasm with evidence of vascular differentiation and Castleman's disease of hyaline vascular type. The two processes blended with each other, with the neoplasm appearing to be continuous with the interfollicular proliferation of small vessels that is typical of Castleman's disease. The lesions behaved aggressively in two cases, both patients having died with metastatic disease. This remarkable association may be viewed as a pathologic manifestation of the intimate functional relationship that exists between the immune and the vascular systems. Other probable examples of this relationship are systemic Castleman's disease associated with Kaposi's sarcoma, localized Castleman's disease associated with vascular hamartoma, histiocytoid hemangioma/angiolymphoid hyperplasia with eosinophilia, and (possibly) angiomatoid malignant fibrous histiocytoma. Perhaps these associations are mediated by the production of angiogenic factors by the activated lymphoid cells.

Entities:  

Mesh:

Year:  1990        PMID: 2356921     DOI: 10.1097/00000478-199007000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

Review 1.  Pelvic mass in 46-year old man.

Authors:  J Flórez; G García-Pardo; T Auguet; J J Sirvent; M Bel; C Richart
Journal:  Postgrad Med J       Date:  1997-06       Impact factor: 2.401

Review 2.  Castleman's disease of the abdomen and pelvis: report of three cases and a review of the literature.

Authors:  H Kiguchi; T Ishii; Y Ishikawa; S Masuda; N Asuwa; K Yamafuji; T Takahashi
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

3.  Morpho-immunophenotypic diversity of Castleman's disease, hyaline-vascular type: with emphasis on a stroma-rich variant and a new pathogenetic hypothesis.

Authors:  A D Danon; J Krishnan; G Frizzera
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 4.  [Castleman's disease in ear, nose, and throat practice].

Authors:  A Schrock; I Gutgemann; S Keiner
Journal:  HNO       Date:  2007-05       Impact factor: 1.284

5.  Inflammatory Pseudotumor Presenting as a Mesosalpingeal Mass.

Authors:  Simona Stolnicu; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2018-09       Impact factor: 2.762

6.  Intestinal lymphangiectasia associated with angiofollicular lymph node hyperplasia (Castleman's disease).

Authors:  S F Moss; D M Thomas; C Mulnier; I G McGill; H J Hodgson
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

Review 7.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

8.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

9.  Acute myelogenous leukemia M5b developed during clinical remission of Castleman disease.

Authors:  Akira Tomonari; Naoki Shirafuji; Arinobu Tojo; Tohru Iseki; Jun Ooi; Itaru Komiya; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.319

Review 10.  Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome.

Authors:  Hongbei Wang; Rosemary L Wieczorek; Michael E Zenilman; Fidelina Desoto-Lapaix; Bimal C Ghosh; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2007-11-20       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.